● Recruiting

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

Condition: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC) · Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) · Sponsor: Olema Pharmaceuticals, Inc.

PhasePhase 1

Planned participants180

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

This is a first-in-human, open-label, multicenter phase 1 study to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of OP-3136, a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor, as monotherapy and in combination with other anticancer agents in participants with advanced solid tumors. This study consists of 2 parts: a dose escalation part (Part 1) and dose expansion part (Part 2).

This description comes directly from the study's public registry record.

Talk to the study team

There may be multiple sites in this clinical trial Olema Clinical Trial Lead · 415-651-7206 · clinical@olema.com

Olema Medical Study Director

Always discuss trial participation with your own doctor first.

Locations (8)

Florida Cancer Specialists	Sarasota, Florida, United States	Recruiting
University Medical Center - New Orleans	New Orleans, Louisiana, United States	Recruiting
Dana-Farber Cancer Institute	Boston, Massachusetts, United States	Recruiting
START - Midwest	Grand Rapids, Michigan, United States	Recruiting
SCRI Oncology Partners	Nashville, Tennessee, United States	Recruiting
START - San Antonio	San Antonio, Texas, United States	Recruiting
START - Mountain Region	West Valley City, Utah, United States	Recruiting
Cancer Research South Australia	Adelaide, South Australia, Australia	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06784193